Separately, Baader Bank set a €19.00 ($23.46) target price on MediGene and gave the stock a buy rating in a research note on Thursday.
MediGene stock opened at €14.32 ($17.68) on Thursday. MediGene has a one year low of €8.53 ($10.53) and a one year high of €19.27 ($23.79). The firm has a market capitalization of $392.27 and a price-to-earnings ratio of -20.75.
TRADEMARK VIOLATION NOTICE: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.tickerreport.com/banking-finance/3300873/medigene-mdg1-given-a-16-50-price-target-at-independent-research.html.
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.